Walid Saliba1, Ofra Barnett, Hedy S Rennert, Gad Rennert. 1. Department of Community Medicine and Epidemiology, Carmel Medical Center, Clalit Health Services, and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa 34362, Israel. saliba_wa@clalit.org.il
Abstract
CONTEXT AND OBJECTIVES: Vitamin D plays a key role in maintaining bone health, but evidence for its nonskeletal effects is inconsistent. This study aims to examine the association between serum 25-hydroxyvitamin D [25(OH)D] levels and all-cause mortality in a large general population cohort. DESIGN, PARTICIPANTS, AND SETTING: Using the computerized database of the largest health care provider in Israel, we identified a cohort of subjects 20 years old or older with serum 25(OH)D levels measured between January 2008 and December 2009. Vital status was ascertained through August 2011. RESULTS: Median follow-up was 28.5 months (interquartile range 23.8-33.5 months); 7,247 of 182,152 participants (4.0%) died. Subjects who died had significantly lower serum 25(OH)D levels (mean 44.8 ± 24.2 nmol/liter) than those alive at the end of follow-up (51.0 ± 23.2 nmol/liter), P < 0.001. After adjustment for age, gender, ethnicity, and seasonality, the hazard ratio (HR) for all-cause mortality was 2.02 [95% confidence interval (CI) 1.89-2.15] for the lowest serum 25(OH)D quartile (<33.8 nmol/liter) compared with the highest. After further adjustment for comorbidity, use of vitamin D supplements and statins, smoking, socioeconomic status, and body mass index, the HR was 1.81 (95% CI 1.69-1.95). This remained, even after adjustment for serum low-density lipoprotein, high-density lipoprotein, calcium level (corrected for serum albumin levels), and glomerular filtration rate, 1.85 (95% CI 1.70-2.01). The fully adjusted HR associated with being in the second 25(OH)D quartile (33.8-49.4 nmol/liter) was 1.25 (95% CI 1.16-1.34). CONCLUSIONS: All-cause mortality is independently and inversely associated with serum 25(OH)D levels at levels less than 50 nmol/liter.
CONTEXT AND OBJECTIVES:Vitamin D plays a key role in maintaining bone health, but evidence for its nonskeletal effects is inconsistent. This study aims to examine the association between serum 25-hydroxyvitamin D [25(OH)D] levels and all-cause mortality in a large general population cohort. DESIGN, PARTICIPANTS, AND SETTING: Using the computerized database of the largest health care provider in Israel, we identified a cohort of subjects 20 years old or older with serum 25(OH)D levels measured between January 2008 and December 2009. Vital status was ascertained through August 2011. RESULTS: Median follow-up was 28.5 months (interquartile range 23.8-33.5 months); 7,247 of 182,152 participants (4.0%) died. Subjects who died had significantly lower serum 25(OH)D levels (mean 44.8 ± 24.2 nmol/liter) than those alive at the end of follow-up (51.0 ± 23.2 nmol/liter), P < 0.001. After adjustment for age, gender, ethnicity, and seasonality, the hazard ratio (HR) for all-cause mortality was 2.02 [95% confidence interval (CI) 1.89-2.15] for the lowest serum 25(OH)D quartile (<33.8 nmol/liter) compared with the highest. After further adjustment for comorbidity, use of vitamin D supplements and statins, smoking, socioeconomic status, and body mass index, the HR was 1.81 (95% CI 1.69-1.95). This remained, even after adjustment for serum low-density lipoprotein, high-density lipoprotein, calcium level (corrected for serum albumin levels), and glomerular filtration rate, 1.85 (95% CI 1.70-2.01). The fully adjusted HR associated with being in the second 25(OH)D quartile (33.8-49.4 nmol/liter) was 1.25 (95% CI 1.16-1.34). CONCLUSIONS: All-cause mortality is independently and inversely associated with serum 25(OH)D levels at levels less than 50 nmol/liter.
Authors: Daniel V Dudenkov; Kristin C Mara; Tanya M Petterson; Julie A Maxson; Tom D Thacher Journal: Mayo Clin Proc Date: 2018-05-02 Impact factor: 7.616
Authors: Soo Lim; Min Joo Kim; Sung Hee Choi; Chan Soo Shin; Kyong Soo Park; Hak Chul Jang; Liana K Billings; James B Meigs Journal: Am J Clin Nutr Date: 2013-01-30 Impact factor: 7.045
Authors: Cedric F Garland; June Jiwon Kim; Sharif Burgette Mohr; Edward Doerr Gorham; William B Grant; Edward L Giovannucci; Leo Baggerly; Heather Hofflich; Joe Wesley Ramsdell; Kenneth Zeng; Robert P Heaney Journal: Am J Public Health Date: 2014-06-12 Impact factor: 9.308
Authors: C Cipriani; E Romagnoli; V Carnevale; R Clerico; J Pepe; M Cilli; D Diacinti; C Savoriti; L Colangelo; S Minisola Journal: J Endocrinol Invest Date: 2013-07-23 Impact factor: 4.256
Authors: Paulette D Chandler; Edward L Giovannucci; Michelle A Williams; Meryl S LeBoff; David W Bates; LeRoi S Hicks Journal: Am J Pharm Benefits Date: 2014
Authors: Christopher T Sempos; Ramón A Durazo-Arvizu; Bess Dawson-Hughes; Elizabeth A Yetley; Anne C Looker; Rosemary L Schleicher; Guichan Cao; Vicki Burt; Holly Kramer; Regan L Bailey; Johanna T Dwyer; Xinli Zhang; Jaime Gahche; Paul M Coates; Mary Frances Picciano Journal: J Clin Endocrinol Metab Date: 2013-05-10 Impact factor: 5.958